

Gisette Reyes-Soffer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5624322/publications.pdf>

Version: 2024-02-01

30
papers

1,372
citations

471509

17
h-index

501196

28
g-index

31
all docs

31
docs citations

31
times ranked

1474
citing authors

#	ARTICLE	IF	CITATIONS
1	Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, ATV0000000000000147.	2.4	207
2	Relationship Between Body Composition and Death in Patients with COVID-19 Differs Based on the Presence of Gastrointestinal Symptoms. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4484-4491.	2.3	7
3	Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation. <i>Pharmacological Research</i> , 2021, 169, 105689.	7.1	29
4	Obesity is independently associated with septic shock, renal complications, and mortality in a multiracial patient cohort hospitalized with COVID-19. <i>PLoS ONE</i> , 2021, 16, e0255811.	2.5	8
5	Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease risk: current status and treatments. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021, 28, 85-89.	2.3	3
6	Life is complicated: so is apoCIII. <i>Journal of Lipid Research</i> , 2019, 60, 1347-1349.	4.2	6
7	Is APOC3 the driver of cardiovascular disease in people with type I diabetes mellitus?. <i>Journal of Clinical Investigation</i> , 2019, 129, 4074-4076.	8.2	5
8	NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2018, 71, 177-192.	2.8	337
9	Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects. <i>Journal of Lipid Research</i> , 2018, 59, 2397-2402.	4.2	43
10	Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes. <i>Current Cardiology Reports</i> , 2017, 19, 7.	2.9	42
11	Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E. <i>Journal of Lipid Research</i> , 2017, 58, 1214-1220.	4.2	18
12	Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans. <i>Circulation</i> , 2017, 135, 352-362.	1.6	185
13	CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1770-1775.	2.4	71
14	The metabolism of lipoprotein (a): an ever-evolving story. <i>Journal of Lipid Research</i> , 2017, 58, 1756-1764.	4.2	67
15	Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans. <i>Science Translational Medicine</i> , 2016, 8, 323ra12.	12.4	27
16	Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 1083-1093.	3.8	23
17	Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 994-1002.	2.4	32
18	Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects. <i>Journal of Clinical Investigation</i> , 2015, 125, 2510-2522.	8.2	67

#	ARTICLE	IF	CITATIONS
19	Abstract 129: Effects of a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor, Alirocumab, on Lipid and Lipoprotein Metabolism in Normal Subjects. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, .	2.4	0
20	Abstract 18390: Effects of a Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Inhibitor, Alirocumab, on Lipid and Lipoprotein Metabolism in Healthy Subjects. <i>Circulation</i> , 2015, 132, .	1.6	1
21	Static and turnover kinetic measurement of protein biomarkers involved in triglyceride metabolism including apoB48 and apoA5 by LC/MS/MS. <i>Journal of Lipid Research</i> , 2014, 55, 1179-1187.	4.2	17
22	Autophagy and cardiometabolic risk factors. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2014, 15, 307-315.	5.7	17
23	Practical Immunoaffinity-Enrichment LC-MS for Measuring Protein Kinetics of Low-Abundance Proteins. <i>Clinical Chemistry</i> , 2014, 60, 1217-1224.	3.2	31
24	Abstract 634: Treatment with Mipomersen Reduces Levels of ApoB-Containing Lipoproteins by Increasing Fractional Removal of VLDL and LDL-apoB Without Reducing VLDL-apob Secretion. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, .	2.4	1
25	Measurement of apo(a) kinetics in human subjects using a microfluidic device with tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2013, 27, 1294-1302.	1.5	31
26	Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial. <i>Diabetes Care</i> , 2013, 36, 422-428.	8.6	43
27	Abstract 120: Effects of Anacetrapib Treatment on CETP Metabolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, .	2.4	0
28	Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1429-1438.	1.8	16
29	Endothelial function in individuals with coronary artery disease with and without type 2 diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 1365-1371.	3.4	20
30	Measures of postprandial lipoproteins are not associated with coronary artery disease in patients with type 2 diabetes mellitus. <i>Journal of Lipid Research</i> , 2009, 50, 1901-1909.	4.2	18